187 related articles for article (PubMed ID: 34084688)
1. Alpelisib-Induced Diabetic Ketoacidosis.
Nguyen P; Musa A; Samantray J
Cureus; 2021 May; 13(5):e14796. PubMed ID: 34084688
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
3. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
[No Abstract] [Full Text] [Related]
5. Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Chang DY; Ma WL; Lu YS
Ther Clin Risk Manag; 2021; 17():193-207. PubMed ID: 33707948
[TBL] [Abstract][Full Text] [Related]
6. Diabetic Ketoacidosis With the Use of Alpelisib in a Patient With Metastatic Breast Cancer Without Diabetes.
Polisetty L; Teresa Selvin S; Tan JW
JCEM Case Rep; 2024 Apr; 2(4):luae023. PubMed ID: 38524964
[TBL] [Abstract][Full Text] [Related]
7. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
8. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
9. Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient.
Fugere T; Roy AM; Makhoul I
Cureus; 2021 Nov; 13(11):e19295. PubMed ID: 34900474
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
12. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
Tankova T; Senkus E; Beloyartseva M; Borštnar S; Catrinoiu D; Frolova M; Hegmane A; Janež A; Krnić M; Lengyel Z; Marcou Y; Mazilu L; Mrinakova B; Percik R; Petrakova K; Rubovszky G; Tokar M; Vrdoljak E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406370
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
14. Alpelisib for the treatment of
Leenhardt F; Alexandre M; Jacot W
Expert Opin Pharmacother; 2021 Apr; 22(6):667-675. PubMed ID: 33622114
[No Abstract] [Full Text] [Related]
15. First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.
Hester A; Henze F; Travi C; Harbeck N; Wuerstlein R
Breast Care (Basel); 2021 Apr; 16(2):129-134. PubMed ID: 34012367
[TBL] [Abstract][Full Text] [Related]
16. ALPELISIB - INDUCED HYPERGLYCEMIA.
Ekanayake PS; Gerwer J; Mccowen K
Acta Endocrinol (Buchar); 2022; 18(1):115-117. PubMed ID: 35975254
[TBL] [Abstract][Full Text] [Related]
17. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Abufaied M; Jumbo U; Alqalalwah A; Hamad MK
Cureus; 2021 Nov; 13(11):e19441. PubMed ID: 34909343
[TBL] [Abstract][Full Text] [Related]
18. Preventing alpelisib-related hyperglycaemia in HR+/HER2-/
Llombart-Cussac A; Pérez-Garcia JM; Ruiz Borrego M; Tolosa P; Blanch S; Fernández-Ortega A; Urruticoechea A; Blancas I; Saura C; Rojas B; Bermejo B; Ponce Lorenzo J; Gion M; Cortez-Castedo P; Llabres E; Galve E; Cueva JF; López A; Alonso-Romero JL; González-Santiago S; Martínez de Dueñas E; Ciruelos E; Martrat G; Gener P; Alcalá-López D; Sampayo-Cordero M; Gómez-Peralta F; Cortés J
EClinicalMedicine; 2024 May; 71():102520. PubMed ID: 38638399
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells.
Krajnak S; Trier JP; Heinzmann PF; Anic K; Heimes AS; Loewe A; Schmidt M; Battista MJ; Hasenburg A; Brenner W
EXCLI J; 2023; 22():114-130. PubMed ID: 36998707
[TBL] [Abstract][Full Text] [Related]
20. S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia.
Thomas K; Germain M; Loch MM
J Investig Med High Impact Case Rep; 2022; 10():23247096221105249. PubMed ID: 35712858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]